Maxcyte Inc (MXCT) Stock Price, Quote & News

Company Profile

MaxCyte, Inc., a life sciences company, discovers, develops, and commercializes cell therapeutics in the United States and internationally. The company's products include ExPERT ATx, a static electroporation instrument for small to medium scale transfection; ExPERT STx, a flow electroporation for protein production and drug development, as well as expression of therapeutic targets for cell-based assays; ExPERT GTx, a flow electroporation for large scale transfection in therapeutic applications;...

Industry: Medical Devices

Sector: Healthcare

Phone: 301 944 1700

Website: www.maxcyte.com

Address:

9713 Key West Avenue, Suite 400, Rockville, United States

highnihilism Oct. 4 at 9:20 AM

0 · Reply

BeefStewart Oct. 4 at 12:22 AM

$MXCT I have to give @GoldmanSlaps full credit for introducing me to this stock via @AlertsAndNews (another account I hadn't been following until Goldman shared a post they made regarding the insider buying at MXCT) after I was on a losing streak. Thank you bro! I hope it goee to the moon! 🙏🙏🙏🙏🙏🙏🙏🙏✨️✨️✨️✨️✨️✨️✨️✨️

0 · Reply

BeefStewart Oct. 3 at 8:08 PM

$MXCT Very solid day and I believe it is just getting started!

1 · Reply

BeefStewart Oct. 3 at 6:09 PM

$MXCT This is an easy double in the next 3-6 months, in my opinion. Look at their cash reserves (anticipating ending the year with 155M), and they just started the process of cutting their workforce. They expect growth in the Asia Pacific market next year, and they anticipate closing 3-5 new SPL deals per year.

0 · Reply

BeefStewart Oct. 3 at 4:05 PM

$MXCT she's squirting again!

0 · Reply

BeefStewart Oct. 3 at 2:40 PM

$MXCT I will reiterate once more that book value was estimated at 1.70-1.80 BEFORE the plan to reduce headcount by 34%. Presently, we are trading in the range of the book value BEFORE that initiative was announced. They have already filed notices with the government of Maryland that they are laying people off. Book value today SHOULD BE much higher than $1.80 per share, in my opinion.

0 · Reply

BeefStewart Oct. 2 at 7:40 PM

$CERS Monster comeback... Funnily enough, $MXCT dropped to 1.46 on Tuesday (September 30th) and then started to rip higher. Looks like Cerus is doing the exact same thing. Both had 1.45 on the bid at one point, but it didn't print for either of them. Wow! Wishing you guys great luck!

0 · Reply

BeefStewart Oct. 2 at 7:22 PM

$ADMA Honestly, this right here. Anyone who has been here since 2021/2022 has potentially made a killing here. Yes, it sucks right now as it's lagging the market, I suppose, but it's still around 7× to nearly 14× for those who bought in around late 2021 - early 2022. Ultimately, management continues to execute well, despite the stock performing poorly since late last year or so. Wishing everyone here great luck. If the price gets really stupid, I might slip a finger in 😏😉 I mean uhhm dip a toe in! 😳🥹🥰🙈🥰 For the time being, I'm very enthusiastic about $MXCT and hoping we see greater optimism in biotech overall! $XBI

0 · Reply

Bombaata Oct. 2 at 4:13 PM

$MXCT $CRBU $PRME $BEAM $CRSP so exciting you had to SPAM 4 other boards... must be a SCAM STOCK

1 · Reply

Mindegap Oct. 2 at 2:57 PM

$MXCT Waiting, waiting for the rest of the world to realize how imporant $MXCT is across all gene editing platforms. $CRBU $PRME $BEAM $CRSP

3 · Reply

MaxCyte Announces Operational Restructuring to Reduce Costs and Accelerate Path to Profitability

Aug 7, 2025, 3:45 AM EDT - 2 months ago

MaxCyte, Inc. (MXCT) Q2 2025 Earnings Call Transcript

Aug 4, 2025, 8:05 AM EDT - 2 months ago

MaxCyte Signs Platform License Agreement with Adicet Bio

Jul 31, 2025, 8:05 AM EDT - 2 months ago

MaxCyte Announces Strategic Platform Licensing Agreement with Anocca AB to Advance TCR-T Cell Therapy Pipeline

Jul 9, 2025, 8:05 AM EDT - 3 months ago

MaxCyte to Report Second Quarter 2025 Financial Results on August 6, 2025

Jul 1, 2025, 1:00 AM EDT - 3 months ago

PHC Announces Exclusive Distribution of MaxCyte® ExPERT™ Platform in Japan

Jun 11, 2025, 2:00 AM EDT - 4 months ago

MaxCyte and Ori Biotech Collaborate to Improve Manufacturing Efficiencies and Broaden Adoption of Autologous Cellular Therapies

May 10, 2025, 11:57 PM EDT - 5 months ago

MaxCyte, Inc. (MXCT) Q1 2025 Earnings Call Transcript

May 7, 2025, 4:05 PM EDT - 5 months ago

MaxCyte Reports First Quarter 2025 Financial Results and Reiterates Full Year 2025 Guidance

Apr 10, 2025, 2:00 AM EDT - 6 months ago

MaxCyte to Report First Quarter 2025 Financial Results on May 7, 2025

Mar 15, 2025, 8:30 AM EDT - 7 months ago

MaxCyte: Strong Revenues, Fast-Growing Cell-Therapy Market, Very Low Share Price

Mar 11, 2025, 7:52 PM EDT - 7 months ago

MaxCyte, Inc. (MXCT) Q4 2024 Earnings Call Transcript

Mar 11, 2025, 4:05 PM EDT - 7 months ago

MaxCyte Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Full Year 2025 Guidance

Feb 12, 2025, 2:00 AM EST - 8 months ago

MaxCyte Signs Strategic Platform License with TG Therapeutics to Advance its Autoimmune Cell Therapeutics Programs

Feb 7, 2025, 2:00 AM EST - 8 months ago

MaxCyte to Report Fourth Quarter and Full Year 2024 Financial Results on March 11, 2025, and Participate in Upcoming Investor Conference

Jan 30, 2025, 10:36 AM EST - 8 months ago

Glancy Prongay & Murray LLP Announces Investigation of MaxCyte, Inc. (MXCT)

Jan 30, 2025, 2:00 AM EST - 8 months ago

MaxCyte® Acquires SeQure Dx to Broaden Cell Engineering Offerings with On-target and Off-target Editing Assessments

Jan 13, 2025, 3:05 AM EST - 9 months ago

MaxCyte Announces Preliminary Unaudited Fourth Quarter and Full Year 2024 Financial Results

Dec 23, 2024, 2:00 AM EST - 10 months ago

MaxCyte Announces Retirement of Board Member Art Mandell

Dec 9, 2024, 2:00 AM EST - 10 months ago

MaxCyte Announces Streamlined Operations and Raises 2024 Revenue Guidance

Nov 13, 2024, 8:05 AM EST - 11 months ago

MaxCyte Celebrates 25 Years of Innovation Driving Cell Engineering-Based Therapeutics

Nov 6, 2024, 10:01 PM EST - 11 months ago

MaxCyte, Inc. (MXCT) Q3 2024 Earnings Call Transcript

Nov 6, 2024, 4:05 PM EST - 11 months ago

MaxCyte Reports Third Quarter 2024 Financial Results and Updates Full Year 2024 Guidance

Oct 31, 2024, 8:05 AM EDT - 1 year ago

MaxCyte to Participate in Two Upcoming Investor Conferences

Oct 15, 2024, 8:05 AM EDT - 1 year ago

MaxCyte Appoints Cynthia Collins to its Board of Directors

Oct 11, 2024, 8:05 AM EDT - 1 year ago

MaxCyte to Report Third Quarter 2024 Financial Results on November 6, 2024

Oct 10, 2024, 8:05 AM EDT - 1 year ago

MaxCyte Appoints Ali Soleymannezhad as Chief Commercial Officer

Oct 4, 2024, 5:19 PM EDT - 1 year ago

Maxcyte: Reaching Financial Inflection With CASGEVY Ramp Up

Sep 16, 2024, 2:00 AM EDT - 1 year ago

MaxCyte Signs Strategic Platform License with Kamau Therapeutics to Accelerate the Development of Cell Therapies for Genetic Diseases

Sep 5, 2024, 4:05 PM EDT - 1 year ago

MaxCyte to Participate in Virtual Craig-Hallum Capital Group Bioprocessing Conference

Aug 7, 2024, 12:09 AM EDT - 1 year ago

MaxCyte, Inc. (MXCT) Q2 2024 Earnings Call Transcript

Aug 6, 2024, 4:05 PM EDT - 1 year ago

MaxCyte Reports Second Quarter and Half-Year 2024 Financial Results and Updates Full Year 2024 Guidance

Jul 9, 2024, 4:05 PM EDT - 1 year ago

MaxCyte to Report Second Quarter 2024 Financial Results on August 6, 2024

May 29, 2024, 8:05 AM EDT - 1 year ago

MaxCyte to Participate in William Blair 44th Annual Growth Stock Conference

May 22, 2024, 8:05 AM EDT - 1 year ago

MaxCyte Signs Strategic Platform License Agreement with Legend Biotech to Accelerate Cell Therapy Discovery and Development

May 11, 2024, 8:35 AM EDT - 1 year ago

MaxCyte, Inc. (MXCT) Q1 2024 Earnings Call Transcript

May 7, 2024, 4:05 PM EDT - 1 year ago

MaxCyte Reports First Quarter 2024 Financial Results and Updates 2024 Guidance

Apr 10, 2024, 8:05 AM EDT - 1 year ago

MaxCyte to Report First Quarter 2024 Financial Results on May 7, 2024

Apr 2, 2024, 8:05 AM EDT - 1 year ago

MaxCyte Signs Strategic Platform License with Be Biopharma to Support the Development of Engineered B Cell Medicines (BCMs)

Mar 12, 2024, 10:40 PM EDT - 1 year ago

MaxCyte, Inc. (MXCT) Q4 2023 Earnings Call Transcript

Mar 12, 2024, 4:05 PM EDT - 1 year ago

MaxCyte Reports Fourth Quarter and Full Year 2023 Financial Results and Reiterates 2024 Guidance

Mar 4, 2024, 4:05 PM EST - 1 year ago

MaxCyte Initiates Full Year 2024 Guidance and Reaffirms 2023 Preliminary Results

Feb 9, 2024, 8:05 AM EST - 1 year ago

MaxCyte to Report Fourth Quarter and Full Year 2023 Financial Results on March 12, 2024 and Participate in Upcoming Investor Conferences

Jan 30, 2024, 8:05 AM EST - 1 year ago

MaxCyte and Wugen Sign Strategic Platform License to Expedite Scale-Up of Clinical and Commercial Manufacturing of Wugen's Investigational Allogeneic, Off-the-Shelf Cell Therapies for Cancers

Jan 23, 2024, 8:05 AM EST - 1 year ago

MaxCyte Signs Strategic Platform License with Imugene to Advance their Cancer Immunotherapy Programs

Jan 8, 2024, 4:05 PM EST - 1 year ago

MaxCyte Announces Preliminary Unaudited Fourth Quarter and Full Year 2023 Financial Results

Jan 3, 2024, 8:05 AM EST - 1 year ago

MaxCyte and Lion TCR form Partnership to Support Global Expansion of Lion TCR's TCR-T Cell Pipeline

Jan 2, 2024, 2:00 AM EST - 1 year ago

MaxCyte Confirms Appointment of Maher Masoud as President, Chief Executive Officer and Director

Dec 11, 2023, 4:05 PM EST - 1 year ago

MaxCyte Announces CEO Transition and Updates Revenue Guidance for 2023

Nov 27, 2023, 8:00 AM EST - 2 years ago

MaxCyte May Benefit From Potential Gene Therapy Approval

highnihilism Oct. 4 at 9:20 AM

0 · Reply

BeefStewart Oct. 4 at 12:22 AM

0 · Reply

BeefStewart Oct. 3 at 8:08 PM

$MXCT Very solid day and I believe it is just getting started!

1 · Reply

BeefStewart Oct. 3 at 6:09 PM

0 · Reply

BeefStewart Oct. 3 at 4:05 PM

$MXCT she's squirting again!

0 · Reply

BeefStewart Oct. 3 at 2:40 PM

0 · Reply

BeefStewart Oct. 2 at 7:40 PM

0 · Reply

BeefStewart Oct. 2 at 7:22 PM

0 · Reply

Bombaata Oct. 2 at 4:13 PM

$MXCT $CRBU $PRME $BEAM $CRSP so exciting you had to SPAM 4 other boards... must be a SCAM STOCK

1 · Reply

Mindegap Oct. 2 at 2:57 PM

$MXCT Waiting, waiting for the rest of the world to realize how imporant $MXCT is across all gene editing platforms. $CRBU $PRME $BEAM $CRSP

3 · Reply

BeefStewart Oct. 2 at 2:34 PM

$MXCT

0 · Reply

BeefStewart Oct. 1 at 5:51 PM

$MXCT strange... jumped on volume and dumped on light volume...

1 · Reply

BeefStewart Oct. 1 at 4:47 PM

$MXCT pulling back on lowish volume...

0 · Reply

BeefStewart Oct. 1 at 3:20 PM

$MXCT volume already over 428k at 11:19 ET

0 · Reply

rooneyray Oct. 1 at 2:59 PM

$MXCT $RGEN $TWST $CLPT This entire sector is undervalued. Let's go gang.

0 · Reply

BeefStewart Oct. 1 at 2:58 PM

$MXCT when searching $MXCT on twitter/X, I found this tweet + image shared by Joseph Angelo (@beachdudeca): Warn Notices Notice Layoffs Layoff Redundancy MaxCyte, Inc. $MXCT, 20 staff cut, Maryland Bell Nursery, 42 staff cut, Maryland

1 · Reply

BeefStewart Oct. 1 at 2:49 PM

$MXCT I believe the volume has just nearly doubled...

0 · Reply

BeefStewart Oct. 1 at 2:47 PM

$MXCT Volume spike! Followed by jump from 1.61 ask to 1.64 ask!

0 · Reply

BeefStewart Oct. 1 at 2:19 PM

$MXCT Looks like yesterday may have been the end of what could have been a shake out and the beginning of a recovery 🥹❤️✨️

0 · Reply

BeefStewart Oct. 1 at 2:10 PM

$MXCT

0 · Reply

BeefStewart Sep. 30 at 8:24 PM

$MXCT Just when it feels like someone is going to release a fiery hot load deep inside your underground parking space, reprieve comes in the most pleasantly surprising way! 🥹🥰✨️🤭🥰

1 · Reply

BeefStewart Sep. 30 at 8:03 PM

$MXCT Wow, what a day! 🥰🥰🥰🥰🕺🏽💃🕺🏽💃🕺🏽💃🕺🏽💃👯‍♀️👯‍♂️🕺🏽💃🥳🥳🥳🥳

0 · Reply

Market Cap	182.30M
Revenue (ttm)	38.63M
Net Income (ttm)	-41.06M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-106.29%
Debt to Equity Ratio	0.00

Volume	882,600
Avg Vol	914,336
Day's Range	N/A - N/A
Shares Out	106.61M
Stochastic %K	74%
Beta	1.23
Analysts	Strong Sell
Price Target	$7.00